Regeneron's Otarmeni was recently FDA approved for patients with OTOF-related hearing loss based on CHORD trial results.
You might like the sound of this news. In a landmark move, the Food and Drug Administration on Thursday approved the first gene therapy for a rare, inherited form of hearing loss. And while these ...
US health officials on Thursday greenlit a first-of-its-kind gene therapy to treat a rare form of hereditary hearing loss, a breakthrough that could pave the way for other such hearing impairment ...
Children born deaf because of a rare condition can now take a drug to restore their hearing after a gene therapy was approved in the U.S., ushering in a new era for the treatment of an inherited form ...
The Food and Drug Administration on Thursday approved Regeneron’s Otarmeni, the first gene therapy for genetic hearing loss. Subscribe to read this story ad-free Get unlimited access to ad-free ...
April 23 (Reuters) - The U.S. Food and Drug Administration has approved Regeneron's (REGN.O), opens new tab gene therapy for a rare genetic form of deafness, the company said on Thursday. This ...
The treatment, the first of its kind, was approved by the Food and Drug Administration on Thursday. “Our baby was born deaf, and now he can hear,” said one parent. By Gina Kolata The Food and Drug ...
The US Food and Drug Administration on Thursday approved the first gene therapy for inherited hearing loss, a one-time treatment that proved to be life-changing for a small number of children in a ...
An experimental gene therapy appears safe and highly effective for restoring hearing to people born with a rare form of deafness, researchers reported Wednesday. The study, the largest and longest to ...
O. Rose Broderick reports on the health policies and technologies that govern people with disabilities’ lives. Before coming to STAT, she worked at WNYC’s Radiolab and Scientific American, and her ...
A gene therapy that can restore sight to people born with degenerative blindness has earned its creators one of science’s most prestigious prizes, often described by its Silicon Valley founders as the ...
Fabry disease is a rare, X-linked genetic lysosomal storage disorder caused by a deficient enzyme called alpha-galactosidase A. Without it, a fatty substance called globotriaosylceramide, or GL-3, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results